Cost-effectiveness of low-molecular-weight heparin compared with aspirin for prophylaxis against venous thromboembolism after total joint arthroplasty

Journal of Bone and Joint Surgery

Volumn 95, Issue 14, 2013, Pages 1256-1264

  Schousboe, John T ^a   Brown, Gregory A ^a  

^a PARK NICOLLET INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; LOW MOLECULAR WEIGHT HEPARIN; ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CHRONIC VEIN INSUFFICIENCY; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK FACTOR; SENSITIVITY ANALYSIS; SURGICAL MORTALITY; SURVIVAL RATE; THROMBOCYTOPENIA; THROMBOSIS PREVENTION; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; VENOUS THROMBOEMBOLISM; VERY ELDERLY; AGE; ARTHROPLASTY; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMICS;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT; ASPIRIN; COST-BENEFIT ANALYSIS; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; VENOUS THROMBOEMBOLISM;

EID: 84884489295     PISSN: 00219355     EISSN: 15351386     Source Type: Journal    
DOI: 10.2106/JBJS.L.00400     Document Type: Article

References (51)

1. Handoll HH, Farrar MJ, McBirnie J, Tytherleigh-Strong G, Milne AA, Gillespie WJ. Heparin, low molecular weight heparin and physical methods for preventing deep vein thrombosis and pulmonary embolism following surgery for hip fractures. Cochrane Database Syst Rev. 2002;(4):CD000305.
2. National Collaborating Centre for Acute Care. Venous thromboembolism: reducing the risk of venous thromboembolism in inpatients undergoing surgery. London: Royal College of Surgeons; 2007.
3. Brown GA. Venous thromboembolism prophylaxis after major orthopaedic surgery: a pooled analysis of randomized controlled trials. J Arthroplasty. 2009; 24(6)(Suppl):77-83.
4. Eikelboom JW, Karthikeyan G, Fagel N, Hirsh J. American Association of Orthopedic Surgeons and American College of Chest Physicians guidelines for venous thromboembolism prevention in hip and knee arthroplasty differ: what are the implications for clinicians and patients? Chest. 2009;135(2):513-20.
5. Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S, Ortel TL, Pauker SG, Colwell CW Jr; American College of Chest Physicians. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2)(Suppl): e278S-325S.
6. Haas SB, Barrack RL, Westrich G, Lachiewicz PF. Venous thromboembolic disease after total hip and knee arthroplasty. J Bone Joint Surg Am. 2008;90(12): 2764-80.
7. Novicoff WM, Brown TE, Cui Q, Mihalko WM, Slone HS, Saleh KJ. Mandated venous thromboembolism prophylaxis: possible adverse outcomes. J Arthroplasty. 2008;23(6)(Suppl 1):15-9.
8. American Academy of Orthopedic Surgeons. Preventing Venous Thromboembolic Disease in Patients Undergoing Elective Hip and Knee Arthroplasty. American Academy of Orthopedic Surgeons, 2011.
9. Januel JM, Chen G, Ruffieux C, Quan H, Douketis JD, Crowther MA, Colin C, Ghali WA, Burnand B. IMECCHI Group. Symptomatic in-hospital deep vein thrombosis and pulmonary embolism following hip and knee arthroplasty among patients receiving recommended prophylaxis: a systematic review. JAMA. 2012;307(3):294-303.
10. Leizorovicz A, Turpie AG, Cohen AT, Wong L, Yoo MC, Dans A; SMART Study Group. Epidemiology of venous thromboembolism in Asian patients undergoing major orthopedic surgery without thromboprophylaxis. The SMART study. J Thromb Haemost. 2005;3(1):28-34.
11. O'Reilly RF, Burgess IA, Zicat B. The prevalence of venous thromboembolism after hip and knee replacement surgery. Med J Aust. 2005;182(4):154-9.
12. Samama CM, Ravaud P, Parent F, Barré J, Mertl P, Mismetti P. Epidemiology of venous thromboembolism after lower limb arthroplasty: the FOTO study. J Thromb Haemost. 2007;5(12):2360-7.
13. Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med. 2003;139(11):893-900.
14. Lee WC, Christensen MC, Joshi AV, Pashos CL. Long-term cost of stroke subtypes among Medicare beneficiaries. Cerebrovasc Dis. 2007;23(1):57-65.
15. Vera-Llonch M, Hagiwara M, Oster G. Clinical and economic consequences of bleeding following major orthopedic surgery. Thromb Res. 2006;117(5):569-77.
16. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood. 2005;106(8):2710-5.
17. Smythe MA, Koerber JM, Mattson JC. The incidence of recognized heparin-induced thrombocytopenia in a large, tertiary care teaching hospital. Chest. 2007; 131(6):1644-9.
18. Pedersen AB, Sorensen HT, Mehnert F, Overgaard S, Johnsen SP. Risk factors for venous thromboembolism in patients undergoing total hip replacement and receiving routine thromboprophylaxis. J Bone Joint Surg Am. 2010;92(12):2156-64.
19. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998;158(6):585-93.
20. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet. 2000;355(9212):1295- 302.
21. Mohr DN, Silverstein MD, Heit JA, Petterson TM, O'Fallon WM, Melton LJ. The venous stasis syndrome after deep venous thrombosis or pulmonary embolism: a population-based study. Mayo Clin Proc. 2000;75(12):1249-56.
22. Ginsberg JS, Turkstra F, Buller HR, MacKinnon B, Magier D, Hirsh J. Postthrombotic syndrome after hip or knee arthroplasty: a cross-sectional study. Arch Intern Med. 2000;160(5):669-72.
23. Kearon C. Natural history of venous thromboembolism. Circulation. 2003; 107(23)(Suppl 1):I22-30.
24. Arias E; Centers for Disease Control. United States life tables, 2004. Natl Vital Stat Rep. 2007;56(9):1-39.
25. Smythe MA, Koerber JM, Fitzgerald M, Mattson JC. The financial impact of heparin-induced thrombocytopenia. Chest. 2008;134(3):568-73.
26. Bullano MF, Willey V, Hauch O, Wygant G, Spyropoulos AC, Hoffman L. Longitudinal evaluation of health plan cost per venous thromboembolismor bleed event in patients with a prior venous thromboembolism event during hospitalization. J Manag Care Pharm. 2005;11(8):663-73.
27. Ollendorf DA, Vera-Llonch M, Oster G. Cost of venous thromboembolism following major orthopedic surgery in hospitalized patients. Am J Health Syst Pharm. 2002 Sep 15;59(18):1750-4.
28. Caprini JA, Botteman MF, Stephens JM, Nadipelli V, Ewing MM, Brandt S, Pashos CL, Cohen AT. Economic burden of long-term complications of deep vein thrombosis after total hip replacement surgery in the United States. Value Health. 2003;6(1):59-74.
29. Bureau of Labor Statistics. Consumer price index. http://www.bls.gov/cpi/ tables.htm. Accessed 2012 Jan 16.
30. Red Book 2010: Pharmacy's Fundamental Reference. 114th ed. Montvale, NJ: Thomson Reuters Physicians' Desk Reference; 2010
31. Ostendorf M, van Stel HF, Buskens E, Schrijvers AJ, Marting LN, Verbout AJ, Dhert WJ. Patient-reported outcome in total hip replacement. A comparison of five instruments of health status. J Bone Joint Surg Br. 2004;86(6):801-8.
32. Creekmore FM, Oderda GM, Pendleton RC, Brixner DI. Incidence and economic implications of heparin-induced thrombocytopenia in medical patients receiving prophylaxis for venous thromboembolism. Pharmacotherapy. 2006;26(10):1438-45.
33. Lenert LA, Soetikno RM. Automated computer interviews to elicit utilities: potential applications in the treatment of deep venous thrombosis. J Am Med Inform Assoc. 1997;4(1):49-56.
34. O'Meara JJ 3rd, McNutt RA, Evans AT, Moore SW, Downs SM. A decision analysis of streptokinase plus heparin as compared with heparin alone for deep-vein thrombosis. N Engl J Med. 1994;330(26):1864-9.
35. Lee HY, Hwang JS, Jeng JS, Wang JD. Quality-adjusted life expectancy (QALE) and loss of QALE for patients with ischemic stroke and intracerebral hemorrhage: a 13-year follow-up. Stroke. 2010;41(4):739-44.
36. Warwick D, Friedman RJ, Agnelli G, Gil-Garay E, Johnson K, FitzGerald G, Turibio FM. Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry. J Bone Joint Surg Br. 2007;89(6):799-807.
37. Guijarro R, Montes J, San Román C, Arcelus JI, Barillari G, Granero X, Monreal M; Findings from the Spanish National Discharge Database. Venous thromboembolism and bleeding after total knee and hip arthroplasty. Thromb Haemost. 2011;105(4):610-5.
38. Beksacx B, González Della Valle A, Anderson J, Sharrock NE, Sculco TP, Salvato EA. Symptomatic thromboembolism after one-stage bilateral THA with a multimodal prophylaxis protocol. Clin Orthop Relat Res. 2007;(463):114-9.
39. Memtsoudis SG, Besculides MC, Gaber L, Liu S, González Della Valle A. Risk factors for pulmonary embolism after hip and knee arthroplasty: a population-based study. Int Orthop. 2009;33(6):1739-45.
40. Mraovic B, Hipszer BR, Epstein RH, Pequignot EC, Parvizi J, Joseph JI. Preadmission hyperglycemia is an independent risk factor for in-hospital symptomatic pulmonary embolism after major orthopedic surgery. J Arthroplasty. 2010;25(1): 64-70.
41. Tick LW, Kramer MH, Rosendaal FR, Faber WR, Doggen CJ. Risk factors for postthrombotic syndrome in patients with a first deep venous thrombosis. J Thromb Haemost. 2008;6(12):2075-81.
42. Agency for Healthcare Research and Quality. Safe practices for better healthcare: summary: a consensus report. 2003. http://www.ahrq.gov/qual/ nqfpract.htm. Accessed 2012 Mar 1.
43. Cram P, Lu X, Kaboli PJ, Vaughan-Sarrazin MS, Cai X, Wolf BR, Li Y. Clinical characteristics and outcomes of Medicare patients undergoing total hip arthroplasty, 1991-2008. JAMA. 2011;305(15):1560-7.
44. Baser O, Supina D, Sengupta N, Wang L, Kwong L. Clinical and cost outcomes of venous thromboembolism in Medicare patients undergoing total hip replacement or total knee replacement surgery. Curr Med Res Opin. 2011;27(2):423-9.
45. Cohen A, Quinlan D. PEP trial. Pulmonary Embolism Prevention. Lancet. 2000;356(9225):247, author reply :250-1.
46. Mahé I, Bergmann JF, Mahé E, Caulin C. PEP trial. Pulmonary Embolism Prevention. Lancet. 2000;356(9225):248, author reply :250-1.
47. Parker M. PEP trial. Pulmonary Embolism Prevention. Lancet. 2000;356(9225):249, author reply :250-1.
48. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists' Collaboration. BMJ. 1994;308(6923):235-46.
49. Dorr LD, Gendelman V, Maheshwari AV, Boutary M, Wan Z, Long WT. Multimodal thromboprophylaxis for total hip and knee arthroplasty based on risk assessment. J Bone Joint Surg Am. 2007;89(12):2648-57.
50. Daniel J, Pradhan A, Pradhan C, Ziaee H, Moss M, Freeman J, McMinn DJ. Multimodal thromboprophylaxis following primary hip arthroplasty: the role of adjuvant intermittent pneumatic calf compression. J Bone Joint Surg Br. 2008;90(5): 562-9.
51. Westrich GH, Bottner F, Windsor RE, Laskin RS, Haas SB, Sculco TP. VenaFlow plus Lovenox vs VenaFlow plus aspirin for thromboembolic disease prophylaxis in total knee arthroplasty. J Arthroplasty. 2006;21(6)(Suppl 2):139-43.